Full Year 2024 Results Key Financial Results Revenue: US$58.8m (up 32% ...

Leerink lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $6 from $7 and keeps a Market Perform rating on the shares after ...

EST Cathie Wood’s ARK Investment buys 653K shares of Recursion Pharmaceuticals (RXRX) todayDiscover the Best Stocks and Maximize Your ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) had soared by 15.8% as of 12:06 p.m. ET on Friday. Did the clinical-stage biotech company report great news? Nope. Instead, the stock's gains ...

Gain insights into Recursion Pharmaceuticals' Q4 2024 earnings call. Discover clinical advancements, key partnerships, and strategic plans for 2025.

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -47.22% and 84.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the ...

The clinical-stage TechBio company posted a loss of $0.53 per share for Q4, wider than the $0.41 loss analysts had forecast. Revenue came in at $4.55 million, significantly below the consensus ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

周二，英伟达 (NVDA.US)持仓概念股盘初集体飙升，截至发稿， 文远知行 (WRD.US)大涨逾28%，上一交易日大涨逾83%；Recursion Pharmaceuticals (RXRX.US)涨逾16%，NEBIUS (NBIS.US)涨超8%，Applied Digital (APLD.US)涨逾5%。

Recursion Pharmaceuticals, Inc.’s RXRX share price has dipped by 10.34%, which has investors questioning if this is right time to buy.

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Friday reported a loss of $178.9 million in its fourth quarter. On a per-share basis, the Salt Lake City-based ...